nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.
Company profile
Ticker
NUVL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Nuvalent Securities Corporation ...
NUVL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
9 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
14 Nov 23
8-K
Nuvalent Announces Pricing of Public Offering of Common Stock
17 Oct 23
424B5
Prospectus supplement for primary offering
17 Oct 23
424B5
Prospectus supplement for primary offering
16 Oct 23
8-K
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
13 Oct 23
Latest ownership filings
144
Notice of proposed sale of securities
27 Mar 24
4
Matthew Shair
27 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
4
Darlene Noci
25 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
4
Emily Conley
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 12.93 mm | 11.03 mm | 7.66 mm | 7.28 mm |
Cash used (since last report) | n/a | n/a | 77.41 mm | 66.04 mm | 45.87 mm | 43.57 mm |
Cash remaining | n/a | n/a | 11.03 mm | 22.39 mm | 42.57 mm | 44.87 mm |
Runway (months of cash) | n/a | n/a | 0.9 | 2.0 | 5.6 | 6.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 118 |
Opened positions | 16 |
Closed positions | 11 |
Increased positions | 56 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 2.56 tn |
Total shares | 83.71 mm |
Total puts | 74.02 k |
Total calls | 122.30 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 25.47 mm | $0.00 |
Deerfield Management | 19.99 mm | $918.99 bn |
FMR | 7.62 mm | $350.27 bn |
Bain Capital Life Sciences Investors | 3.58 mm | $164.45 bn |
Perceptive Advisors | 2.46 mm | $113.24 bn |
Fairmount Funds Management | 2.45 mm | $112.71 bn |
BLK Blackrock | 2.43 mm | $111.71 bn |
Bain Capital Life Sciences Fund II | 2.40 mm | $0.00 |
Vanguard | 2.13 mm | $98.11 bn |
Paradigm Biocapital Advisors | 1.64 mm | $75.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | Yes | Yes | 77.37 | 105 | 8.12 k | 238,522 |
25 Mar 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | Yes | Yes | 76.74 | 1,895 | 145.42 k | 238,627 |
25 Mar 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | No | Yes | 77.37 | 1,955 | 151.26 k | 1,687,198 |
25 Mar 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | No | Yes | 76.74 | 35,545 | 2.73 mm | 1,689,153 |
22 Mar 24 | Darlene Noci | Class A Common Stock | Sell | Dispose S | No | Yes | 78.72 | 600 | 47.23 k | 33,300 |
22 Mar 24 | Darlene Noci | Class A Common Stock | Sell | Dispose S | No | Yes | 77.94 | 6,300 | 491.02 k | 33,900 |
22 Mar 24 | Darlene Noci | Class A Common Stock | Sell | Dispose S | No | Yes | 77.25 | 13,100 | 1.01 mm | 40,200 |
22 Mar 24 | Darlene Noci | Class A Common Stock | Option exercise | Acquire M | No | Yes | 14.4 | 10,000 | 144.00 k | 53,300 |
22 Mar 24 | Darlene Noci | Class A Common Stock | Option exercise | Acquire M | No | Yes | 1.08 | 10,000 | 10.80 k | 43,300 |
22 Mar 24 | Darlene Noci | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 14.4 | 10,000 | 144.00 k | 34,161 |
News
JP Morgan Maintains Overweight on Nuvalent, Raises Price Target to $98
6 Mar 24
Guggenheim Assumes Nuvalent at Buy, Announces Price Target of $99
28 Feb 24
BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $102
28 Feb 24
Recap: Nuvalent Q4 Earnings
27 Feb 24
Nuvalent Q4 EPS $(0.62) Down From $(0.49) YoY, Cash Balance of $719.9M
27 Feb 24
Press releases
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
5 Mar 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
27 Feb 24
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
12 Feb 24
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1 Feb 24